Humanigen to Present and Participate at Multiple Upcoming Investor and Industry Conferences
Humanigen, Inc . (Nasdaq: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate, lenzilumab™, today announced that the Comp
ir.humanigen.com